News

Janssen Biotech, along with AbbVie’s Pharmacyclics, has developed Imbruvica, which is a first-in-class Bruton's tyrosine kinase inhibitor. iNNOVATE is a Pharmacyclics-sponsored, randomized, placebo-controlled and double-blind study designed to

C-Bridge Capital has invested $50 million to fund Everest and has assembled a veteran leadership team with an established track record in both the development of innovative drugs

The trial is being conducted in the United States and top line data is expected in Q3 2018. The Phase 2 study is a randomized, double-blind, vehicle-controlled, multicenter,

The FDA has approved the once-weekly analogue of human glucagon-like peptide-1 (GLP-1) receptor agonist in 0.5mg and 1mg therapeutic dosages with the injection indicated to be used as

University of Queensland scientists are hoping clinical trials could soon be underway for people with lung, pancreatic and colorectal cancers that have not responded to other therapies. UQ

Under the terms of the agreement, PsychoGenics is providing access to its powerful phenotypic discovery platforms, including its SmartCube system and machine learning expertise, for unbiased discovery of

The investigational compound, which has been designed to selectively inhibit IL-23 by binding to its p19 subunit, was evaluated in the late-stage study dubbed IMMhance, In the first

Mitobridge will become a wholly-owned subsidiary of Astellas following the close of the acquisition. Under the 2013 partnership agreements, Astellas and Mitobridge have collaborated to discover and develop

MOR202 is MorphoSys's proprietary investigational antibody against CD38, for which recruitment of a European Phase 1/2a clinical study in relapsed/refractory multiple myeloma has been concluded. Under the terms